BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 6, 2026
Home » Monash University

Articles Tagged with ''Monash University''

Endocrine/metabolic

Monash University describes new melanocortin MC5 receptor agonists

Jan. 12, 2026
Monash University has identified cyclic peptides acting as melanocortin MC5 receptor (MC5R) agonists reported to be useful for the treatment of diabetes, obesity, cardiomyopathy, heart failure, renal disorders, Rabson Mendenhall syndrome, Donohue syndrome and lipodystrophy.
Read More
Concept art for cells receptors, inhibitors
Inflammatory

Structure-based development of next-generation GSTO1-1 inhibitors

Nov. 5, 2025
No Comments
Glutathione transferase omega-1 (GSTO1-1) helps drive inflammatory disorders and cancers by activating the NLRP3 inflammasome and promoting production of pro-inflammatory interleukin-1b. Numerous small molecules have been generated to inhibit the enzyme, but none has progressed to clinical trials, mostly because of off-target activity or poor pharmacokinetics.
Read More
Art concept for RNA and protein

Genetic code governing how mutations affect mRNA uncovered

Oct. 30, 2025
By Tamra Sami
No Comments
Researchers at Monash University in Melbourne, Australia, have uncovered the hidden code governing how genetic mutations affect RNA splicing and result in disease. The researchers were able to identify the specific mutations that cause changes in RNA splicing, Sureshkumar Balasubramanian, the lead researcher at Monash University’s School of Biological Sciences, told BioWorld.
Read More
Art concept for RNA and protein
Genetic/congenital

Genetic code governing how mutations affect mRNA uncovered

Oct. 28, 2025
By Tamra Sami
No Comments
Researchers at Monash University in Melbourne, Australia, have uncovered the hidden code governing how genetic mutations affect RNA splicing and result in disease. The researchers were able to identify the specific mutations that cause changes in RNA splicing, Sureshkumar Balasubramanian, the lead researcher at Monash University’s School of Biological Sciences, told BioWorld.
Read More
Ovarian cancer illustration
Immuno-oncology

Dual knockout of DGK-α and -ζ enhances TAG-72 CAR T-cell antitumor efficacy in ovarian cancer

May 22, 2025
No Comments
Ovarian cancer remains a leading cause of cancer-related deaths among women, with high recurrence rates and resistance to chemotherapy. CAR T-cell therapies present limited efficacy in solid tumors due to tumor heterogeneity and immune suppression in the tumor microenvironment.
Read More
Petri dish
Infection

Immuron and Monash University collaborate to target antimicrobial resistance

Jan. 17, 2025
Immuron Ltd. has signed a new research collaboration agreement with Monash University to develop new therapeutic drug candidates targeting antimicrobial-resistant pathogens. This work will utilize the Immuron technology platform, and the experience of the Biomedicine Discovery Institute research team.
Read More
Microscope with slide
Inflammatory

Discovery of MRTF/SRF pathway inhibitor for the treatment of fibrotic diseases

Sep. 17, 2024
Cincera Therapeutics Pty Ltd. and Monash University co-presented the phenotypic drug discovery of CIN-244, a novel MRTF/SRF pathway inhibitor reported to be potentially useful for the treatment of fibrotic disease, particularly liver, lung and renal fibrosis.
Read More
The calcitonin gene related peptide (CGRP, yellow) bound to its receptor
Dermatologic

Neuropeptide released by pain neurons promotes wound healing by interacting with immune system

April 11, 2024
By Subhasree Nag
Wound healing is a highly specialized dynamic process for the repair of damaged/injured tissues through an intricate mechanism. Any failure in the normal wound healing process results in abnormal scar formation, and a chronic state which is more susceptible to infections. Researchers from Monash University in Australia and Osaka University in Japan have demonstrated that the removal of a specific subtype of sensory neurons containing the Nav1.8+ ion channel significantly impairs skin wound repair and muscle regeneration following injury.
Read More
Neurology/Psychiatric

Australian researchers describe new MERTK inhibitors and PET imaging agents for diagnosis and treatment of MS

Jan. 9, 2024
Researchers from Florey Neuroscience Institutes, Monash University and Olivia Newton-John Cancer Research Institute have identified fluorine-radiolabeled compounds acting as tyrosine-protein kinase Mer (MERTK) inhibitors and also as positron emission tomography (PET) imaging agents reported to be useful for the diagnosis and treatment of multiple sclerosis (MS).
Read More
Natural killer cell attacking cancer cell
Immuno-oncology

Transcription factors Ikaros and Aiolos drive immune response

Jan. 8, 2024
By Tamra Sami
Researchers at Monash University in Melbourne have discovered that transcription factors Ikaros and Aiolos work by binding to AP-1 transcriptional complexes and driving their transcription, which regulates thousands of genes in the human body.
Read More
Previous 1 2 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 6, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • Strategy compass

    Bio Korea 2026: US policy risks shift to execution framework

    BioWorld
    Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
  • Regulatory actions for May 5, 2026

    BioWorld
    Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing